SPUR™ Validation in COPD
To know more about our studies, visit our SPUR Research website.
Objective
The aim of this study was to explore the validity of the SPUR™ tool as a holistic Patient-Reported Outcome Measure of medication adherence in Chronic Obstructive Pulmonary Disease (COPD). The study has been published in Patient Preference and Adherence.
The 2 key outputs to keep in mind
- The predictive validity of SPUR™ to measure adherence of chronic patients living with COPD is confirmed.
- SPUR™ score is correlated with CAT (COPD Assessment Test) and can identify worsening symptom severity.
Methodology
100 adult patients suffering from COPD from a large London NHS Trust with at least 1 inhaler prescribed for a minimum of 6 months prior to the study were surveyed.
Patients provided demographic and health-related information and filled out the following questionnaires:
- SPUR™
- Validated PROMs measuring adherence
o The Inhaler Adherence Scale (IAS)
o The Medication Possession Ratio (MPR) - Symptom severity assessment tool:
o The COPD Assessment Test (CAT)
Spearman’s rank correlation coefficient was calculated to examine correlations between the various PROMs and SPUR.
A Chi-square analysis was conducted to explore the relationship between the CAT and SPUR.
Conclusion
SPUR™ score is correlated with established Patient-Reported Outcomes (PROMs) in this study. Its predictive validity to measure medication adherence in COPD is confirmed.
SPUR™ is also significantly associated to COPD symptom severity. This finding could be applied in clinical practice to prospectively address patient outcomes linked to poor medication adherence.
See also
Beyond DTx: Is Pharma Missing the Bigger Picture in Digital Health?
A multiple-cohort analysis of the SPUR 6/24 patient-reported adherence tool
